MedTrace Logo

Study of Kidney Circulating Cell-free DNA in Patients With Acute Kidney Failure

NCT05399420 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2022-06-01

No results posted yet for this study

Summary

The amount of total circulating DNA has been shown to increase in patients with acute renal failure. Nevertheless, it is currently not currently possible to prove the renal origin of this circulating DNA. Recently, in healthy subjects, teams have shown that it is possible to identify its tissue origin of circulating DNA. CGenetix is a MedTech company which develops on an identical principle an in vitro diagnostic test capable of identifying and quantifying renal degradation during an acute trauma. The objective of this study is to evaluate the sensitivity of the proposed technology to detect circulating DNA of renal origin released into the general circulation in patients with acute organic and functional renal failure. Patients with functional or organic kidney deficiency will be included and the kidney biomarkers develop by CGenetix will be compared between these 2 groups of patients.

Conditions

  • Kidney Failure, Acute

Interventions

DIAGNOSTIC_TEST

Blood sampling

One additional blood tube will be collected for each patient included in the study using PAXgene Blood ccfDNA Tubes

Sponsors & Collaborators

  • Centre Hospitalier Sud Francilien

    collaborator OTHER

  • CGenetix

    lead INDUSTRY

Principal Investigators

  • Valerie Caudwell, MD · Centre Hospitalier Sud Francilien

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-10
Primary Completion
2022-12-20
Completion
2023-01-10

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05399420 on ClinicalTrials.gov